drugset / Trial / NCT04283006
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.
Timeline
- Start
- 2018-05-23
- Primary completion
- 2023-05-23
- Completion
- 2028-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD20/CD22 dual Targeted CAR T-cells | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | CD20/CD22 dual Targeted CAR T-cells | Cell therapy | 5e+06 cells/kg | Intravenous |